http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1011608-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92279befeb1f1b64435d036840fa73ec |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-33 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 1999-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58aaabb4e773c4073b60a5e071b9bec7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14e7e4ebc30b53ebe4dd326b0b9c6ef3 |
| publicationDate | 2000-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1011608-A2 |
| titleOfInvention | Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs |
| abstract | A pharmaceutical composition comprises an agent such as an adenosine A2a agonist agent and/or nucleic acid comprising an oligonucleotide(oligo) that is anti-sense to an adenosine A1, A2a, A2b or A3 receptor gene, mRNA, flanking regions or regions bridging the intro/exon borders, which oligos are effective to prevent, alleviate or inhibit adenosine-mediated cardiac, pulmonary and/or renal functional difficulties, damage or failure, such as those observed in diseases and conditions such as ARDS, hypoxia, etc. or associated with the administration of therapeutic and diagnostic agents such as adenosine cysplatin, metal ion-containing agents, etc., mixtures thereof, and optionally a surfactant, a carrier and other therapeutic and diagnostic agents and other formulation components. The composition is provided in the form of various formulations that are, for example, effective for preventing or alleviating bronchoconstriction, allergy and/or inflammation associated with ARDS, RDS, etc., deleterious side effects observed upon treatment of SVT patients, upon administration of cardiac stress tests or imaging tests, etc. |
| priorityDate | 1998-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1317.